Pharmaceutical Manufacturing

Pharmaceutical manufacturing puts two non-negotiable constraints on capital equipment: it has to meet cGMP requirements, and it has to hit validated output targets. A tablet press, a capsule filler, a blister packaging line, or a sterile vial fill-finish system is not just production equipment; it is part of the regulatory submission. Equipment changes trigger change control processes. The investment decision is made long before the line runs, and the financing has to close on a timeline that serves the project, not the lender's internal process. We finance pharmaceutical production equipment from solid-dose lines to liquid fill operations to packaging systems. Minimum transaction is $50,000; application-only approval is available up to $400,000; most deals fund in one to two weeks. New and used equipment are both eligible, including used equipment purchased from a decommissioned plant or a drug manufacturer that exited a product line.

Production Equipment Across Pharmaceutical Dosage Forms

Solid-dose manufacturing is the largest segment. Rotary tablet presses at production scale, such as those from Fette, Korsch, or Manesty, range from $250,000 for a refurbished 30-station press to over $1.5 million for a high-speed 75-station machine capable of 400,000-plus tablets per hour. Granulation and blending equipment, fluid-bed processors, and coating pans are companion assets in a solid-dose suite; we finance the full suite in a single transaction rather than requiring each piece to be financed separately.

Liquid filling operations include both non-sterile aqueous fills for oral liquid products and sterile vial-and-syringe fill-finish for injectable products. A non-sterile liquid filling line with a piston or peristaltic filler, capper, and labeler typically runs $150,000 to $600,000. Sterile fill-finish isolators and barrier systems for injectable products are significantly more complex, with costs that frequently exceed $1 million for an integrated restricted-access barrier system. Liquid filling machine financing covering both non-sterile and cleanroom configurations is within our program.

Packaging equipment for pharmaceutical output includes blistering machines, bottle filling and capping lines, carton erectors, and serialization equipment. Blister packaging machines for unit-dose solid-dose products range from $100,000 for a simple thermoform-fill-seal unit to $600,000-plus for a high-speed rotary blistering line with integrated vision and reject systems. Serialization and track-and-trace equipment required for DSCSA compliance has driven a wave of capital investment as manufacturers have moved to meet federal traceability requirements. Labeling and serialization equipment is financed as a standalone upgrade for manufacturers adding compliance capability to existing lines.

Cold-chain storage and controlled-environment systems are a related category. Pharmaceutical refrigerators and freezers, stability chambers, and environmental monitoring systems used in API storage and product holding qualify for equipment financing alongside the production assets. We treat the full cold-chain and controlled-environment investment as part of the same project when it is submitted that way.

Underwriting for Pharmaceutical Manufacturers

Pharmaceutical manufacturers range from billion-dollar contract drug manufacturers to single-product specialty pharma companies to small CDMO operations with a few dozen employees. The financing structures scale accordingly. A small specialty pharma operation adding a second tablet press at $350,000 qualifies for application-only review with no financial statements required. A CDMO adding a $2 million fill-finish line to accommodate a new client contract submits three months of bank statements and business financials and typically receives a decision within a week.

Lenders outside the equipment finance space sometimes struggle with pharmaceutical manufacturers because the regulatory capital expenditure cycle looks lumpy on a cash flow statement. Validation costs are expense-line items; equipment goes on the balance sheet. A company that has spent the last 18 months in validation and startup for a new product line may show compressed operating margins at exactly the moment it needs to add the next production asset. Equipment lenders read this pattern correctly as investment activity, not operational deterioration.

Equipment leasing is a useful structure for pharmaceutical manufacturers that prefer to keep capital expenditures off-balance-sheet for covenant purposes or that expect to upgrade equipment at the end of a five-year product lifecycle. Operating leases for production equipment are available for qualified borrowers with a clear end-of-term plan for the asset.

Financing Options Beyond Standard Equipment Loans

Pharmaceutical manufacturers with owned equipment on their facility floor have options beyond new-asset financing. A Cash-Out Refinance for Production Line Equipment on a paid-down tablet press or filling line converts the asset equity into working capital. The proceeds can fund API inventory, validation expenses, regulatory submissions, or other cash needs that do not have a natural equipment-financing structure. The equipment stays in production; the equity moves to the operating account.

Sale-leaseback is the parallel structure for equipment that is owned free and clear. The manufacturer sells the equipment to a lender at appraised value, books the cash, and makes monthly lease payments to retain use of the equipment. This is particularly common for manufacturers that acquired equipment in a plant acquisition and now want to free the embedded equity without disrupting production. Nutraceutical and supplement manufacturers that operate under dietary supplement GMP and share similar capsule-filling and tablet-pressing equipment with pharma shops use this same structure frequently.

For manufacturers launching new product lines or adding capacity for a specific contract, No-Money-Down Equipment Financing preserves cash for the startup costs associated with the new line while keeping the equipment on a structured payment plan. The decision between a down payment and no-money-down depends on rate, term, and how tight the operating cash flow is during the startup period. Medical device manufacturers that also produce drug-device combination products face a parallel capital planning challenge and qualify for the same financing programs.

Finance the Equipment Your Next Product Line Requires

Pharmaceutical capital projects run on regulatory timelines, not lender cycles. We close fast. Tell us the equipment, the project timeline, and the amount. Minimum transaction $50,000; application-only up to $400,000; funding in one to two weeks.